265 related articles for article (PubMed ID: 24918341)
1. Intrathecal infusion of BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord.
Yin HZ; Yu S; Hsu CI; Liu J; Acab A; Wu R; Tao A; Chiang BJ; Weiss JH
Exp Neurol; 2014 Nov; 261():1-9. PubMed ID: 24918341
[TBL] [Abstract][Full Text] [Related]
2. l-Serine Reduces Spinal Cord Pathology in a Vervet Model of Preclinical ALS/MND.
Davis DA; Cox PA; Banack SA; Lecusay PD; Garamszegi SP; Hagan MJ; Powell JT; Metcalf JS; Palmour RM; Beierschmitt A; Bradley WG; Mash DC
J Neuropathol Exp Neurol; 2020 Apr; 79(4):393-406. PubMed ID: 32077471
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal infusion of a Ca(2+)-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS.
Yin HZ; Tang DT; Weiss JH
Exp Neurol; 2007 Oct; 207(2):177-85. PubMed ID: 17719032
[TBL] [Abstract][Full Text] [Related]
4. β-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS.
de Munck E; Muñoz-Sáez E; Miguel BG; Solas MT; Ojeda I; Martínez A; Gil C; Arahuetes RM
Environ Toxicol Pharmacol; 2013 Sep; 36(2):243-255. PubMed ID: 23688553
[TBL] [Abstract][Full Text] [Related]
5. BMAA selectively injures motor neurons via AMPA/kainate receptor activation.
Rao SD; Banack SA; Cox PA; Weiss JH
Exp Neurol; 2006 Sep; 201(1):244-52. PubMed ID: 16764863
[TBL] [Abstract][Full Text] [Related]
6. Metabotropic glutamate receptor 1 mediates the electrophysiological and toxic actions of the cycad derivative beta-N-Methylamino-L-alanine on substantia nigra pars compacta DAergic neurons.
Cucchiaroni ML; Viscomi MT; Bernardi G; Molinari M; Guatteo E; Mercuri NB
J Neurosci; 2010 Apr; 30(15):5176-88. PubMed ID: 20392940
[TBL] [Abstract][Full Text] [Related]
7. BMAA and Neurodegenerative Illness.
Cox PA; Kostrzewa RM; Guillemin GJ
Neurotox Res; 2018 Jan; 33(1):178-183. PubMed ID: 28540663
[TBL] [Abstract][Full Text] [Related]
8. BMAA--an unusual cyanobacterial neurotoxin.
Vyas KJ; Weiss JH
Amyotroph Lateral Scler; 2009; 10 Suppl 2():50-5. PubMed ID: 19929732
[TBL] [Abstract][Full Text] [Related]
9. Creating a Simian Model of Guam ALS/PDC Which Reflects Chamorro Lifetime BMAA Exposures.
Banack SA; Cox PA
Neurotox Res; 2018 Jan; 33(1):24-32. PubMed ID: 28478528
[TBL] [Abstract][Full Text] [Related]
10. Chronic BMAA exposure combined with TDP-43 mutation elicits motor neuron dysfunction phenotypes in mice.
Arnold FJ; Burns M; Chiu Y; Carvalho J; Nguyen AD; Ralph PC; La Spada AR; Bennett CL
Neurobiol Aging; 2023 Jun; 126():44-57. PubMed ID: 36931113
[TBL] [Abstract][Full Text] [Related]
11. Editor's Highlight: Embryonic Exposure to the Environmental Neurotoxin BMAA Negatively Impacts Early Neuronal Development and Progression of Neurodegeneration in the Sod1-G93R Zebrafish Model of Amyotrophic Lateral Sclerosis.
Powers S; Kwok S; Lovejoy E; Lavin T; Sher RB
Toxicol Sci; 2017 May; 157(1):129-140. PubMed ID: 28123103
[TBL] [Abstract][Full Text] [Related]
12. L-BMAA induced ER stress and enhanced caspase 12 cleavage in human neuroblastoma SH-SY5Y cells at low nonexcitotoxic concentrations.
Okle O; Stemmer K; Deschl U; Dietrich DR
Toxicol Sci; 2013 Jan; 131(1):217-24. PubMed ID: 23047912
[TBL] [Abstract][Full Text] [Related]
13. Preconditioning, induced by sub-toxic dose of the neurotoxin L-BMAA, delays ALS progression in mice and prevents Na
Anzilotti S; Brancaccio P; Simeone G; Valsecchi V; Vinciguerra A; Secondo A; Petrozziello T; Guida N; Sirabella R; Cuomo O; Cepparulo P; Herchuelz A; Amoroso S; Di Renzo G; Annunziato L; Pignataro G
Cell Death Dis; 2018 Feb; 9(2):206. PubMed ID: 29434186
[TBL] [Abstract][Full Text] [Related]
14. Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis.
Graber DJ; Hickey WF; Harris BT
J Neuroinflammation; 2010 Jan; 7():8. PubMed ID: 20109233
[TBL] [Abstract][Full Text] [Related]
15. Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS).
Van Dyke JM; Smit-Oistad IM; Macrander C; Krakora D; Meyer MG; Suzuki M
Exp Neurol; 2016 Mar; 277():275-282. PubMed ID: 26775178
[TBL] [Abstract][Full Text] [Related]
16. beta-N-methylamino-l-alanine induces oxidative stress and glutamate release through action on system Xc(-).
Liu X; Rush T; Zapata J; Lobner D
Exp Neurol; 2009 Jun; 217(2):429-33. PubMed ID: 19374900
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Long-term, Low-dose β-N-methylamino-L-alanine (BMAA) Exposures in Adult SOD
Weeks RD; Banack SA; Howell S; Thunga P; Metcalf JS; Green AJ; Cox PA; Planchart A
Neurotox Res; 2023 Oct; 41(5):481-495. PubMed ID: 37552461
[TBL] [Abstract][Full Text] [Related]
18. The cyanobacteria derived toxin Beta-N-methylamino-L-alanine and amyotrophic lateral sclerosis.
Banack SA; Caller TA; Stommel EW
Toxins (Basel); 2010 Dec; 2(12):2837-50. PubMed ID: 22069578
[TBL] [Abstract][Full Text] [Related]
19. Animal models of BMAA neurotoxicity: a critical review.
Karamyan VT; Speth RC
Life Sci; 2008 Jan; 82(5-6):233-46. PubMed ID: 18191417
[TBL] [Abstract][Full Text] [Related]
20. Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels.
Bendotti C; Tortarolo M; Suchak SK; Calvaresi N; Carvelli L; Bastone A; Rizzi M; Rattray M; Mennini T
J Neurochem; 2001 Nov; 79(4):737-46. PubMed ID: 11723166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
